Meeting Report: The 2009 San Antonio Breast Cancer Symposium

Understanding the role of antiangiogenesis therapies in metastatic disease and optimizing treatment of patients with HER2-positive disease were common themes.

The San Antonio Breast Cancer Symposium (SABCS; December 9–13, 2009) has been a forum for the latest basic science and clinical research in breast cancer for 31 years. The Editor-in-Chief of Journal Watch Oncology and Hematology, William J. Gradishar, MD, discusses several important studies of therapy in the metastatic and early-stage disease settings. Readers are encouraged to visit the SABCS website for additional information on these and other topics in breast cancer.

Bevacizumab plus Chemotherapy in Metastatic Breast Cancer

The RIBBON-1 study (JW Oncol Hematol Jun 16 2009) showed that the antiangiogenesis agent bevacizumab — a monoclonal antibody directed against vascular endothelial growth factor (VEGF) — plus chemotherapy extended progr…

Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)